The chief operating officer of Bristol-Myers Squibb said Eli Lilly's rival Effient blood clot preventer will be a "niche" product if approved and the TRITON study found it either harmed or offered no benefit to three types of patients.
"There are three important subgroups of patients that seem to derive either net harm or no clinical advantages" from Effient, Lamberto Andreotti told analysts in a conference call.
No comments:
Post a Comment